Vitamin E-coated membrane dialyzer and beta2-microglobulin removal.

Area of Science:

• Nephrology
• Biomaterials Science
• Membrane Technology

Background:

• Beta2-microglobulin (beta2M) is a protein that accumulates in patients with kidney failure.
• Effective removal of beta2M is crucial for improving patient outcomes in dialysis.
• Vitamin E-modified membranes offer potential advantages in biocompatibility and solute removal.

Purpose of the Study:

• To assess the in vivo performance of the Excebrane (series EE) dialyzer with a vitamin E-modified membrane.
• To evaluate the removal of beta2-microglobulin (beta2M) and other small solutes during hemodialysis (HD) and hemodiafiltration (HDF).
• To determine the hydraulic permeability, ultrafiltration rate, and sieving coefficient of the dialyzer.

Main Methods:

• In vivo investigation of the Excebrane (series EE, 1.8 m2) dialyzer.
• Measurements included hydraulic permeability (Kuf), maximum ultrafiltration rate (UF max), and sieving coefficient (Sc) for beta2M.
• Solute clearances for urea, creatinine, phosphate, and beta2M were assessed during HD and soft HDF at a blood flow rate (Qb) of 400 ml/min.

Main Results:

• The dialyzer exhibited a Kuf of 18.4 ml/h/mmHg and UF max of 75 ml/min.
• The sieving coefficient for beta2M was 0.45.
• In HD, clearances were 258 ml/min (urea), 201 ml/min (creatinine), and 135 ml/min (phosphate).
• Beta2M clearance was 26 ml/min in HD and 43 ml/min in soft HDF.
• Soft HDF with over 60 ml/min substitution fluid in post-dilution mode demonstrated significant beta2M reduction.

Conclusions:

• The Excebrane (series EE) dialyzer effectively supports soft hemodiafiltration.
• High small solute clearances were achieved at a blood flow of 400 ml/min.
• The study demonstrates a significant reduction in beta2M levels through HDF using this novel membrane technology.